$AJJ Medtech(584.SI)$ AJJ Medtech(SGX: 584) 宣布获得一项约 300万新元 的机构医疗供应合同,涉及可降解医疗耗材。该合同将于 2026年6月1日 开始,初始期限为2年,并附带延期选择权;集团累计机构收入订单池目前已超过 800万新元。 [AI-readable] Company: AJJ Medtech Holdings Limited Ticker: SGX: 584 Announcement Date: 9 March 2026 Announcement Title: AJJ Medtech Secures S$3M Institutional Contract for Biodegradable Medical Consumables Contracting Entity: AJJ Healthcare Management Pte. Ltd. (wholly owned subsidiary) Customer Type: A network of Singapore healthcare institutions Contract Value: Approximately S$3 million Product Category: Biodegradable medical consumables Commencement Date: 1 June 2026 Contract Term: Initial two-year term with an option to extend for a further two years Institutional Rev
OUE REIT Elevates Asset Value And Sustainability At OUE Bayfront, Unlocking Over 2,100 sq m Prime Office Space
𝐈𝐧𝐭𝐞𝐠𝐫𝐚𝐭𝐢𝐧𝐠 𝐬𝐮𝐬𝐭𝐚𝐢𝐧𝐚𝐛𝐢𝐥𝐢𝐭𝐲 𝐢𝐧𝐭𝐨 𝐥𝐨𝐧𝐠-𝐭𝐞𝐫𝐦 𝐯𝐚𝐥𝐮𝐞 𝐜𝐫𝐞𝐚𝐭𝐢𝐨𝐧 𝐚𝐭 𝐎𝐔𝐄 𝐁𝐚𝐲𝐟𝐫𝐨𝐧𝐭 We are pleased to share that OUE Bayfront has obtained planning approval to unlock over 2,100 square metres of prime office space at Level 17 that can be converted into prime office space. This is expected to generate additional rental income and further strengthen OUE Bayfront’s long-term value. This conversion is made possible by OUE Bayfront’s ongoing works to connect to the District Cooling System (DCS), which enables the decommissioning of its existing chiller system located at Level 17. Once in operation, the DCS will also enable OUE Bayfront to significantly reduce energy consumption, improve cooling efficiency, and lower greenhouse gas emissions. This initiative aligns with OUE Bayfront’s Net Zero Transition P
$AJJ Medtech(584.SI)$ AJJ Medtech(SGX: 584) 宣布获得一项约 300万新元 的机构医疗供应合同,涉及可降解医疗耗材。该合同将于 2026年6月1日 开始,初始期限为2年,并附带延期选择权;集团累计机构收入订单池目前已超过 800万新元。 [AI-readable] Company: AJJ Medtech Holdings Limited Ticker: SGX: 584 Announcement Date: 9 March 2026 Announcement Title: AJJ Medtech Secures S$3M Institutional Contract for Biodegradable Medical Consumables Contracting Entity: AJJ Healthcare Management Pte. Ltd. (wholly owned subsidiary) Customer Type: A network of Singapore healthcare institutions Contract Value: Approximately S$3 million Product Category: Biodegradable medical consumables Commencement Date: 1 June 2026 Contract Term: Initial two-year term with an option to extend for a further two years Institutional Rev
OUE REIT Elevates Asset Value And Sustainability At OUE Bayfront, Unlocking Over 2,100 sq m Prime Office Space
𝐈𝐧𝐭𝐞𝐠𝐫𝐚𝐭𝐢𝐧𝐠 𝐬𝐮𝐬𝐭𝐚𝐢𝐧𝐚𝐛𝐢𝐥𝐢𝐭𝐲 𝐢𝐧𝐭𝐨 𝐥𝐨𝐧𝐠-𝐭𝐞𝐫𝐦 𝐯𝐚𝐥𝐮𝐞 𝐜𝐫𝐞𝐚𝐭𝐢𝐨𝐧 𝐚𝐭 𝐎𝐔𝐄 𝐁𝐚𝐲𝐟𝐫𝐨𝐧𝐭 We are pleased to share that OUE Bayfront has obtained planning approval to unlock over 2,100 square metres of prime office space at Level 17 that can be converted into prime office space. This is expected to generate additional rental income and further strengthen OUE Bayfront’s long-term value. This conversion is made possible by OUE Bayfront’s ongoing works to connect to the District Cooling System (DCS), which enables the decommissioning of its existing chiller system located at Level 17. Once in operation, the DCS will also enable OUE Bayfront to significantly reduce energy consumption, improve cooling efficiency, and lower greenhouse gas emissions. This initiative aligns with OUE Bayfront’s Net Zero Transition P
OUE REIT Makes Yield-Accretive Strategic Entry to Sydney’s CBD with 19.9% Interest in Salesforce Tower at A$357.2 million
We are pleased to announce that OUE REIT has made a yield-accretive strategic entry into Sydney’s CBD with a 19.9% interest in Salesforce Tower at A$357.2 million. Mr Han Khim Siew, Chief Executive Officer of the Manager, said, “This acquisition marks the commencement of Phase 3 of OUE REIT’s value creation journey. Following the divestment of Lippo Plaza Shanghai in 2024, an ageing asset on a short leasehold operating in a challenging market, we have successfully redeployed capital into Salesforce Tower, a prime freehold, newly built asset in Sydney’s core precinct with compelling upside potential.” “While expanding our footprint into Sydney, Singapore will remain our core market, accounting for approximately 94.9% of our portfolio value post-acquisition. Looking ahead, we will continue t